A phase 3 randomized, open-label study of nivolumab (anti-PD-1; BMS-936558; ONO-4538) versus investigator's choice chemotherapy (ICC) in patients with advanced melanoma after prior anti-CTLA-4 therapy Meeting Abstract
| Authors: | Weber, J. S.; Minor, D. R.; D'Angelo, S. P.; Hodi, F. S.; Gutzmer, R.; Neyns, B.; Hoeller, C.; Khushalani, N. I.; Miller, W. H.; Grob, J. J.; Lao, C.; Linette, G.; Grossmann, K.; Hassel, J. C.; Lorigan, P.; Maio, M.; Sznol, M.; Lambert, A.; Yang, A.; Larkin, J. |
| Abstract Title: | A phase 3 randomized, open-label study of nivolumab (anti-PD-1; BMS-936558; ONO-4538) versus investigator's choice chemotherapy (ICC) in patients with advanced melanoma after prior anti-CTLA-4 therapy |
| Meeting Title: | 39th ESMO Congress (ESMO 2014) |
| Journal Title: | Annals of Oncology |
| Volume: | 25 |
| Issue: | Suppl. 4 |
| Meeting Dates: | 2014 Sep 26-30 |
| Meeting Location: | Madrid, Spain |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2014-09-01 |
| Language: | English |
| ACCESSION: | WOS:000346901000006 |
| DOI: | 10.1093/annonc/mdu438.34 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: LBA3_PR -- Source: Wos |
